Does the New FDA Pill for Teen HCM Work?
If your teenager has symptomatic obstructive hypertrophic cardiomyopathy and the next conversation at the HCM clinic has been about septal myectomy or alcohol ablation, there's now a daily pill on the table. On September 30, 2026, the FDA cleared Camzyos (mavacamten) for patients 12 and older who weigh at least 30 kg. In the trial that got it approved, no teen's pumping function dropped below the safety threshold. The catch: that trial was 44 adolescents studied for 28 weeks. A real option, not a settled answer.
For a long time, if a teenager with obstructive HCM stayed short of breath on a beta-blocker, the next step was surgical. A surgeon shaved down the thickened septum, or a cardiologist induced a controlled infarction with alcohol to thin it. Both work. Both are irreversible, and both mean sending a kid to a center that does enough of them to do them well. The pediatric approval of Camzyos changes that choice. There's now an FDA-approved daily pill that unblocks the outflow tract in teens, built on the same mechanism that already works in adults.
What the drug does
HCM thickens the heart muscle. In the obstructive form, the thickened septum and a misbehaving mitral valve leaflet choke off blood as the ventricle contracts. That's where the breathlessness, chest pain, and near-fainting come from. Mavacamten quiets the sarcomere itself: it binds cardiac myosin and keeps more of it in a resting state, so the heart stops squeezing too hard. The outflow tract opens, filling pressures fall, and the heart does less work for the same output.
That same mechanism is also the main hazard. Dial contraction down too far and the ejection fraction drops. The whole monitoring program is built around catching that line early.
The pediatric trial
SCOUT-HCM randomized 44 symptomatic adolescents, ages 12 to under 18, to mavacamten or placebo for 28 weeks. They started with heavy outflow obstruction, averaging around 79 mm Hg with Valsalva. By week 28, the drug cut that provoked gradient by about 48 mm Hg more than placebo did. No teen's ejection fraction fell below 50% during the main evaluation. Side effects looked like placebo.
That's a hemodynamic win on an echo number. It isn't yet proof that teens on mavacamten feel better, exercise longer, or avoid surgery in meaningful numbers. Those were secondary outcomes in a 44-patient study, kept small because this disease is uncommon in kids. The hard question is how far to lean on the adult data to fill in the rest.
Reading across from adults
The adult evidence is substantial and consistent. In EXPLORER-HCM, 251 adults on mavacamten for 30 weeks showed real functional gains, not just a lower gradient: peak oxygen uptake rose by about 1.4 mL/kg/min more than placebo, more patients improved by at least one NYHA class, and health status on the Kansas City Cardiomyopathy Questionnaire climbed about 9 points more. In VALOR-HCM, which enrolled adults already referred for septal reduction surgery, about 84% avoided the procedure or no longer met criteria for it through 128 weeks on the drug. Long-term extensions out to around 180 weeks show the gradient relief holding and the heart remodeling in the right direction.
The pediatric gradient drop looks a lot like what adults get. That's the basis for expecting symptom and surgery-avoidance benefits in teens too. It's also where the uncertainty lives. Twenty-eight weeks in 44 adolescents is a reasonable bridge, not a replacement, for the longer trials this will eventually need.
How this stacks up against surgery
The real decision for most families isn't drug versus nothing. It's drug versus a procedure, after beta-blockers and disopyramide have run their course.
| Option | How it works | Evidence in people under 18 | Key trade-offs |
|---|---|---|---|
| Camzyos (mavacamten) | Daily pill that quiets cardiac myosin so the heart contracts less forcefully | One 44-patient, 28-week trial (SCOUT-HCM); gradient drop like adults, pumping function preserved | Likely lifelong daily use; scheduled echoes under REMS; CYP2C19 genotype guides dose; about $89,500 a year; benefits reverse if stopped |
| Surgical septal myectomy | Open-heart operation that shaves the thickened septum | Decades of experience at specialized centers, including in children | One-time procedure; durable; requires a high-volume center; usual surgical risks |
| Alcohol septal ablation | Catheter-delivered alcohol that infarcts a slice of septum | Mostly adult data; limited pediatric experience | Less invasive than myectomy; risk of heart block and pacemaker; outcomes depend on anatomy |
| Beta-blocker or disopyramide | Slow the heart and reduce contractility | Standard first-line therapy | Often not enough once a teen is clearly symptomatic |
What the daily reality looks like
Camzyos is only dispensed through a REMS program. In practice that means a certified prescriber, enrollment paperwork, a baseline echocardiogram, and follow-up echoes on a schedule to catch a falling ejection fraction before it becomes a problem. The drug is cleared by CYP2C19, so genotype guides the starting and maximum dose.
Across adult registries and extensions, roughly 4% to 11% of patients drop below 50% ejection fraction at some point. Nearly all recover when the drug is paused and resumed at a lower dose. New atrial fibrillation runs around 6% to 14% over longer follow-up. Pregnancy is a contraindication. The wholesale price is about $89,500 a year, retail runs about $9,300 to $10,200 per 30 capsules, and there's no generic. Patient-assistance programs from the manufacturer are the usual route when insurance pushes back.
Who this is actually for
The label is specific, and it matters. Camzyos is for a teen who is 12 or older, weighs at least 30 kg, has obstructive physiology on echo, is symptomatic at NYHA class II or III despite standard medical therapy, and has a baseline ejection fraction of 55% or better. The adult trial of mavacamten in nonobstructive HCM didn't show symptom or exercise benefit, so this isn't a drug for every thickened heart. It's a drug for the specific group where blood is being obstructed on its way out of the ventricle.
If that's your teen, the approval turns a surgical decision into a two-option conversation at a specialized HCM center. The pill isn't a one-time fix. The benefit depends on taking it, and the gradient tends to come back if the drug stops. That's a different kind of commitment than myectomy, which is one hard thing then done. Neither is obviously better in the abstract. The right answer depends on anatomy, how a family weighs a procedure against a lifelong medication, and whether CYP2C19 metabolism, drug interactions, and insurance make the pill realistic to stay on.
What would change the picture
The approval rests on 44 teenagers and 28 weeks of a surrogate on an echo. What would move this from a legitimate option to a default is bigger: a longer and larger pediatric trial, or a pooled registry, that measures what families actually want to know. Does a teen on mavacamten exercise more, feel better, and skip surgery at the rates adults do? What happens to growth, arrhythmias, and ejection fraction over years, not months? And when pediatric HCM guidelines next update, how will they place the pill alongside myectomy for a symptomatic 15-year-old? Until that fills in, Camzyos deserves a serious seat at the HCM-clinic table for the right teen, not a reflex prescription.